Preceptis Medical said today that it launched trial of its Hummingbird tympanostomy tube system.
The Plymouth, Minn.-based company’s Hummingbrid TTS tympanostomy tube system is designed to reduce pain for pediatric patients undergoing ear tube procedures, allowing moderate, conscious sedation with no need for general anesthesia.
The 1st patient in the prospective, office-based study was enrolled by principal investigator Dr. Frank Rimmel at St. Paul, Minn.’s Health Partners Clinic, Preceptis said.
“The company has taken a careful approach to establishing the safety of the Hummingbird in a hospital setting for even the littlest children who require ear tubes. The next step is to demonstrate the Hummingbird’s ability to allow the ENT to safely treat them in-clinic, too,” CEO Steve Anderson said in a press release.
The company also announced the peer reviewed publication of a report on its Hummingbird system, led by head author Dr. Shelagh Cofer of the Mayo Clinic. The paper was published in the Otolaryngology Head and Neck Journal.
Earlier this month, Preceptis filed an SEC filing showing the company is seeking up to $1 million in financing, with a minimum investment of $25,000 required.